Wolfgang Schuette

Summary

Country: Germany

Publications

  1. doi request reprint EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study
    Wolfgang Schuette
    Department of Internal Medicine II, Hospital Martha Maria, Halle Dölau, Halle, Germany
    Cancer Epidemiol Biomarkers Prev 24:1254-61. 2015
  2. doi request reprint A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer
    Wolfgang H W Schuette
    Department of Internal Medicine II, Hospital Martha Maria, Halle Dölau, Halle, Germany
    Clin Lung Cancer 14:215-23. 2013
  3. pmc Randomized phase II study of palifermin for reducing dysphagia in patients receiving concurrent chemoradiotherapy for locally advanced unresectable non-small cell lung cancer
    Wolfgang Schuette
    Krankenhaus Martha Maria Halle Doelau, Klinik Innere Medizin II, Halle Saale, Germany
    J Thorac Oncol 7:157-64. 2012
  4. doi request reprint Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide
    Sylke Nagel
    Hospital Martha Maria, Halle Doelau, Germany
    Clin Lung Cancer 12:62-9. 2011
  5. doi request reprint Randomized phase III trial of docetaxel plus carboplatin with or without levofloxacin prophylaxis in elderly patients with advanced non-small cell lung cancer: the APRONTA trial
    Wolfgang Schuette
    Klinik fuer Innere Medizin II, Krankenhaus Martha Maria Halle Dölau, Halle, Germany
    J Thorac Oncol 6:2090-6. 2011
  6. ncbi request reprint Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel
    Wolfgang Schuette
    Martha Maria City Hospital Halle Doelau, Halle, Germany
    J Clin Oncol 23:8389-95. 2005
  7. pmc Second-line treatment of stage III/IV non-small-cell lung cancer (NSCLC) with pemetrexed in routine clinical practice: evaluation of performance status and health-related quality of life
    Wolfgang Schuette
    Hospital Martha Maria, Halle Doelau, Department of Internal Medicine II, Halle, Germany
    BMC Cancer 12:14. 2012
  8. doi request reprint Six-minute walk distance and dyspnoea scores to assess the course of COPD exacerbation in elderly patients
    Thomas Blankenburg
    Second Medical Clinic, Hospital Martha Maria Halle Doelau, Halle, Germany
    Clin Respir J 7:261-7. 2013
  9. doi request reprint CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status
    Wolfgang Schuette
    Department of Internal Medicine II, Hospital Martha Maria Halle Doelau, Halle, Germany Electronic address
    Clin Lung Cancer 16:447-56. 2015
  10. ncbi request reprint Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer
    Wolfgang Schuette
    2nd Medical Department, City Hospital Martha Maria Halle Doelau, Halle, Germany
    Clin Lung Cancer 7:133-7. 2005

Collaborators

Detail Information

Publications10

  1. doi request reprint EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study
    Wolfgang Schuette
    Department of Internal Medicine II, Hospital Martha Maria, Halle Dölau, Halle, Germany
    Cancer Epidemiol Biomarkers Prev 24:1254-61. 2015
    ..We investigated the clinicopathologic characteristics associated with EGFR mutations and their impact on real-world treatment decisions and outcomes in Caucasian patients with advanced NSCLC...
  2. doi request reprint A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer
    Wolfgang H W Schuette
    Department of Internal Medicine II, Hospital Martha Maria, Halle Dölau, Halle, Germany
    Clin Lung Cancer 14:215-23. 2013
    ..This phase II study evaluated pemetrexed plus cisplatin and pemetrexed plus carboplatin as first-line treatments for stage IIIB/IV NSCLC...
  3. pmc Randomized phase II study of palifermin for reducing dysphagia in patients receiving concurrent chemoradiotherapy for locally advanced unresectable non-small cell lung cancer
    Wolfgang Schuette
    Krankenhaus Martha Maria Halle Doelau, Klinik Innere Medizin II, Halle Saale, Germany
    J Thorac Oncol 7:157-64. 2012
    ..This study assessed the efficacy and safety of palifermin in reducing dysphagia from CT/RT followed by consolidation chemotherapy (CT)...
  4. doi request reprint Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide
    Sylke Nagel
    Hospital Martha Maria, Halle Doelau, Germany
    Clin Lung Cancer 12:62-9. 2011
    ..Addition of darbepoetin alfa to chemotherapy lowered the need for blood transfusions and did not affect measures of survival and objective response...
  5. doi request reprint Randomized phase III trial of docetaxel plus carboplatin with or without levofloxacin prophylaxis in elderly patients with advanced non-small cell lung cancer: the APRONTA trial
    Wolfgang Schuette
    Klinik fuer Innere Medizin II, Krankenhaus Martha Maria Halle Dölau, Halle, Germany
    J Thorac Oncol 6:2090-6. 2011
    ..To examine the effect of levofloxacin prophylaxis on infection rates during chemotherapy with docetaxel plus carboplatin in elderly patients with advanced non-small cell lung cancer...
  6. ncbi request reprint Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel
    Wolfgang Schuette
    Martha Maria City Hospital Halle Doelau, Halle, Germany
    J Clin Oncol 23:8389-95. 2005
    ..A phase III study to determine whether a weekly docetaxel schedule improves the therapeutic index compared with the classic 3-weekly schedule...
  7. pmc Second-line treatment of stage III/IV non-small-cell lung cancer (NSCLC) with pemetrexed in routine clinical practice: evaluation of performance status and health-related quality of life
    Wolfgang Schuette
    Hospital Martha Maria, Halle Doelau, Department of Internal Medicine II, Halle, Germany
    BMC Cancer 12:14. 2012
    ..This prospective, non-interventional study evaluated performance status (PS) and health-related quality of life (HR-QoL) during second-line pemetrexed treatment in routine clinical practice...
  8. doi request reprint Six-minute walk distance and dyspnoea scores to assess the course of COPD exacerbation in elderly patients
    Thomas Blankenburg
    Second Medical Clinic, Hospital Martha Maria Halle Doelau, Halle, Germany
    Clin Respir J 7:261-7. 2013
    ..Physical performance and dyspnoea are of prognostic relevance in stable COPD. The issue investigated was to assess the course of COPD exacerbations to find parameters that describe this situation better...
  9. doi request reprint CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status
    Wolfgang Schuette
    Department of Internal Medicine II, Hospital Martha Maria Halle Doelau, Halle, Germany Electronic address
    Clin Lung Cancer 16:447-56. 2015
    ..Results were compared with those obtained in a control group of patients who received a pemetrexed/cisplatin regimen only...
  10. ncbi request reprint Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer
    Wolfgang Schuette
    2nd Medical Department, City Hospital Martha Maria Halle Doelau, Halle, Germany
    Clin Lung Cancer 7:133-7. 2005
    ..The objective of this phase II trial was to evaluate the activity of gemcitabine/irinotecan in patients with relapsed SCLC...